Ilypsa, Inc. Completes Enrollment of Phase 2 Clinical Trial of ILY101 For Patients With Chronic Kidney Disease On Hemodialysis

Published: Feb 06, 2007

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal disorders, announced today that it has completed enrollment of the company’s Phase 2 clinical trial of ILY101 in the United States. ILY101 is a novel phosphate binding agent for the treatment of hyperphosphatemia, a serious complication in patients with kidney disease on dialysis.

Back to news